Newark, Delaware, January 26, 2026 – Molecular Imaging Services (MIS), a leading provider of advanced imaging solutions, today announced the appointment of Christopher Pusey as Chief Executive Officer. In this role, Pusey will lead the company’s strategic growth initiatives, drive operational excellence, and oversee MIS’s continued expansion across advanced PET/CT and cardiac PET imaging services.
Pusey brings more than 15 years of leadership experience spanning healthcare services, private equity, and multi-site operations. He is widely recognized for building scalable organizations, driving profitable growth, and leading teams through complex operational transformations.
“Christopher’s depth of experience scaling healthcare platforms, executing strategic acquisitions, and building high-performing teams makes him the ideal leader for MIS as we enter our next phase of growth,” said Matt Haney, President of Molecular Imaging Services. “His background aligns perfectly with our mission to help providers successfully deploy and operate advanced molecular imaging programs.”
Most recently, Pusey served as Chief Executive Officer of inReach Health, where he scaled the company’s revenue from $14 million to $60 million, increased EBITDA from less than $2 million to over $10.0 million, and grew the organization from three employees to more than 200. During his tenure, he led five strategic acquisitions, expanded service lines, and built a robust executive leadership team.
Prior to inReach Health, Pusey held senior leadership and investment roles at KRG Capital Partners, a $2 billion middle-market private equity firm, where he led transaction diligence, portfolio operations, and board-level initiatives across multiple industries. His earlier career includes executive and operational leadership roles across healthcare services, technology, and multi-unit consumer businesses.
“I am excited to join MIS at such a pivotal time for molecular imaging,” said Christopher Pusey. “PET/CT and cardiac PET continue to play an increasingly critical role in precision medicine. I look forward to partnering with the MIS team and our clients to expand access, enhance operational performance, and deliver meaningful clinical and financial outcomes.”
As CEO, Pusey will focus on expanding MIS’s national footprint, accelerating the adoption of cardiac PET and oncology PET/CT, strengthening operational, regulatory, and reimbursement support services, and driving sustainable, long-term growth for MIS’s imaging partners.
About Molecular Imaging Services, LLC (MIS)
MIS is a leading provider of turnkey molecular imaging solutions, specializing in the development, implementation, and management of PET/CT and SPECT imaging programs. MIS supports healthcare organizations with comprehensive operational, clinical, and regulatory expertise to ensure seamless and effective imaging service delivery.
Related Posts
